Co-Authors
This is a "connection" page, showing publications co-authored by ANDRAS HECZEY and DAVID STEFFIN.
Connection Strength
2.263
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.988
-
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
Score: 0.944
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.209
-
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Jan 20; e31557.
Score: 0.062
-
Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma. Res Sq. 2024 Apr 11.
Score: 0.059